Scarica l'app Stockscreener
5.81
12.38%
0.64
Dopo l'orario di chiusura:
6.16
0.35
+6.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$5.17
Aprire:
$4.354
Volume 24 ore:
19.03M
Relative Volume:
6.53
Capitalizzazione di mercato:
$1.65B
Reddito:
-
Utile/perdita netta:
$-125.04M
Rapporto P/E:
-7.0854
EPS:
-0.82
Flusso di cassa netto:
$-122.99M
1 W Prestazione:
+56.18%
1M Prestazione:
+73.95%
6M Prestazione:
+297.95%
1 anno Prestazione:
+111.27%
Intervallo 1D:
$4.3401
$6.46
Intervallo di 1 settimana:
$3.36
$6.49
Portata 52W:
$1.01
$6.49
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO
Confronta ERAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
5.81 | 1.47B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
Erasca’s general counsel Garner sells $670,812 in shares By Investing.com - Investing.com India
Erasca’s general counsel Garner sells $670,812 in shares - Investing.com
Assessing Erasca (ERAS) Valuation After FDA Trial Hold And New ERAS-0015 Patent - simplywall.st
Why Erasca Inc. stock appeals to analystsMarket Activity Report & Technical Buy Zone Confirmation - ulpravda.ru
How geopolitical tensions affect Erasca Inc. stockTrend Reversal & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Rate Cut: How Erasca Inc. stock responds to policy changesPortfolio Gains Report & Smart Swing Trading Alerts - ulpravda.ru
Is Erasca Inc. stock a buy for dividend growth2025 Volatility Report & Low Risk Investment Opportunities - ulpravda.ru
What's Going With Cancer Biotech Erasca Stock On Thursday? - Benzinga
Erasca price target raised to $2 from $1 at BofA - MSN
Erasca Stock Pre-Market (-14%) : FDA Places Partial Clinical Hold on ERAS-4001 Trial - Trefis
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
Erasca stock pulls back after 25% jump, Stifel cites competitor data By Investing.com - Investing.com Canada
Erasca stock pulls back after 25% jump, Stifel cites competitor data - Investing.com India
Erasca Inc stock hits 52-week high at $3.80 - Investing.com
Erasca Inc stock hits 52-week high at $3.80 By Investing.com - Investing.com Nigeria
User | custercountychief.comErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Erasca initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Erasca stock with Overweight rating, $5 price target - Investing.com UK
Upcoming EventsErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
BPASErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
B of A Securities Upgrades Erasca (ERAS) - MSN
Fund Flows: How geopolitical tensions affect Erasca Inc stock2025 Market Sentiment & Real-Time Price Movement Reports - moha.gov.vn
Erasca (NASDAQ:ERAS) Trading Up 4.1% – Should You Buy? - Defense World
Aug Spikes: How Erasca Inc stock responds to policy changesJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - moha.gov.vn
Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
Did Index Inclusion and New RAS Patent Just Shift Erasca's (ERAS) Investment Narrative? - simplywall.st
Are Erasca Inc (ERAS) shares a good deal now? - uspostnews.com
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Treasury Yields: Is Erasca Inc stock a buy on dipsWeekly Profit Summary & AI Powered Market Entry Strategies - moha.gov.vn
Why Erasca Inc. stock could be next big winnerWeekly Loss Report & Stock Portfolio Risk Management - Улправда
Will Erasca Inc. stock remain a Wall Street favoritePortfolio Update Summary & Risk Controlled Swing Trade Alerts - Улправда
Buyback Watch: Is Erasca Inc. stock a buy on dipsMarket Activity Summary & Daily Chart Pattern Signals - DonanımHaber
Aug Weekly: How Erasca Inc. stock responds to policy changesJuly 2025 Momentum & Free Long-Term Investment Growth Plans - DonanımHaber
Momentum Shift: Why Erasca Inc. stock could be next big winner2025 Geopolitical Influence & Comprehensive Market Scan Reports - Улправда
Erasca (ERAS) Valuation Check After ERAS-0015 Patent Extension and New Chief Scientific Officer Appointment - simplywall.st
Erasca Inc stock hits 52-week high at $3.68 - Investing.com India
Shareholder Erasca Foundation Files To Sell 8,333 Of Erasca Inc [ERAS] - TradingView — Track All Markets
Erasca Inc stock hits 52-week high at $3.68 By Investing.com - Investing.com Nigeria
Erasca (ERAS) Extends ERAS-0015 Patent to 2043 and Strengthens RAS Pipeline Momentum - simplywall.st
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Erasca price target raised to $5 from $4 at Mizuho - MSN
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Erasca, Inc Secures U.S. Patent Protection Through 2043 for ERAS-0015 - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):